Defense Health Program Department of Defense Bone Marrow Failure Research Program Anticipated Funding Opportunities for Fiscal Year 2021 (FY21)

How to Apply: 

The FY21 Defense Appropriations Act provides funding to the Department of Defense Bone Marrow Failure Research Program (BMFRP) to support research of exceptional merit that focus on bone marrow failure diseases. The managing agent for the anticipated Program Announcements/Funding Opportunities is the Congressionally Directed Medical Research Programs (CDMRP) at the U.S. Army Medical Research and Development Command (USAMRDC).

 

The FY21 BMFRP Program Announcements and General Application Instructions for the following award mechanisms are posted on the Grants.gov website.

 

The objective of the FY21 BMFRP is to fund scientifically meritorious research focused on BMF diseases. Investigator‐initiated research is encouraged in the areas of congenital or acquired BMF. Studies focused on BMF syndromes and their progression to other malignancies, such as leukemia, are acceptable. However, research primarily focused on myeloproliferative neoplasms, leukemia, or other malignancies is discouraged. Stem cell biology studies and translational projects, including bone marrow transplantation studies, should be clearly related to BMF diseases.

 

https://cdmrp.army.mil/funding/bmfrp

 

Idea Development Award – Preproposal due July 9, 2021

  • Established Investigator: Independent investigators at or above the level of Associate Professor (or equivalent) or an Assistant Professor (or equivalent) with 10 years or more from his/her first faculty appointment (or equivalent) by the application submission deadline.
  • Early Career Investigators: Independent investigators at the level of Assistant Professor (or equivalent), and within 10 years from his/her first faculty appointment (or equivalent) by the application submission deadline.
  • Supports innovative ideas and high-impact approaches based on scientifically sound evidence in order to move toward the vision to understand and cure bone marrow failure (BMF) diseases.
  • Proposed research should have a high probability of revealing new avenues of investigation.
  • Research project should include a well–formulated, testable hypothesis and a well-developed and articulated research approach.
  • Must address at least one of the FY21 BMFRP IDA Focus Areas.
  • Strong BMF research team.
  • May include relevant preliminary data.
  • Clinical trials are not allowed.
  • Translational potential should be considered and described.
  • Pre-application is required; application is by invitation only.
    • The maximum period of performance is 3 years.
  • The maximum allowable funding for the entire period of performance is $450,000 in direct costs (plus indirect costs).

 

Investigator-Initiated Research Award (IIRA) – Preproposal due July 9, 2021

Investigators at or above the level of Assistant Professor (or equivalent) by the application submission deadline.

  • Two funding levels of intent:

Ø  Funding Level 1: Supports studies that further develop ideas, expand upon key discoveries, and have the potential to make significant advances in BMF research, patient care, and/or quality of life. Correlative studies to existing clinical trials/studies are encouraged.

Translational potential should be considered and described.

  • Funding Level 2: Investigational New Drug (IND)-enabling efforts The proposed studies should be empirical in nature, product driven, and focused on the accumulation of data to support an IND application to the U.S. Food and Drug Administration.  Applicants are required to identify lead BMF therapy candidate(s), and transition plans should be considered and adequately described.
  • Emphasis on Research Approach and Impact.
  • Strong BMF research team.
  • Preliminary data required.
  • Clinical trials are not allowed.
  • Must address at least one of the FY21 BMFRP IIRA Focus Areas.
  • Partnering PI Option: Allows two PIs, termed Initiating and Partnering PIs, to collaborate on a single application.

Pre-application is required; application is by invitation only

Funding Level 1:

  • The maximum period of performance is 3 years.
  • Maximum funding of $600,000 in direct costs (plus indirect costs).

Funding Level 2: IND-enabling efforts

  • The maximum period of performance is 4 years.
  • Maximum funding of $800,000 in direct costs (plus indirect costs).

 

A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Program Announcements and General Application Instructions that will be available for electronic downloading from the Grants.gov website. The application package containing the required forms for each award mechanism will also be found on Grants.gov. A listing of all CDMRP and other USAMRDC extramural funding opportunities can be obtained on the Grants.gov website by performing a basic search using CFDA Number 12.420. 

 

For email notification when Program Announcements are released, subscribe to program-specific news and updates under “Email Subscriptions” on the eBRAP homepage at https://eBRAP.org. For more information about the BMFRP or other CDMRP-administered programs, please visit the CDMRP website (https://cdmrp.army.mil).

 

Point of Contact:

CDMRP Help Desk
301-682-5507
help@eBrap.org

External Deadline: 
Friday, July 9, 2021
Funding Source: 
External
Funding Level: 
Research